Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0040822 (tremor)
 18,428 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Terbutaline, a selective beta2-adrenergic receptor stimulator was given to 10 patients with chronic bronchitis. The effects of the drug were tested by measurements of forced expiratory volume in 1 sec (FEV1), peak expiratory flow rate (PEFR), heart rate, blood pressure and blood gas analysis. The measurements were performed before and 1, 2, 4, 5, and 6 h after oral administration of placebo, 2.5 mg, or 5.0 mg terbutaline. Terbutaline caused a significant dose-related increase in FEV1 and PEFR as compared with placebo. The maximal effects were found at the 4-h measurement and were still present at the measurements performed at 6 h. Heart rate, blood pressure and arterial oxygen tension (PaO2) were not significantly affected. Four patients experienced side effects as tremor and/or heart palpitations. It is concluded that orally administered terbutaline may be an important therapeutical agent in the treatment of chronic bronchitis.
 ...
PMID:Effect of a single graded dose of terbutaline tablets in patients with chronic bronchitis and bronchoconstriction. A double-blind, placebo, cross-over study. 36 41

The primary adverse effect of stimulation of beta2-adrenergic receptors is elicitation of tremor. Tremor measurements in response to beta2-adrenergic receptor stimulation were performed in a quantitative manner using a modified miniature semiconductor accelerometer in African green monkeys. The accelerometer was taped to the middle finger tip of anesthetized monkeys, and recordings of onset, duration and peak tremor responses were obtained. The selective beta2-adrenergic agonist, salbutamol (0.5 mg/kg i.v.), caused a marked increase in tremor which started within 5 min following injection and lasted for approximately 60 min. The finger tremor response was not visible, but was measurable by the accelerometer, and the increase in tremor was significantly greater from baseline within 10 min. Plasma K+ concentrations were markedly decreased within the first 15 min and remained at low steady-state concentrations during the 60-min recordings. The tremor response was abolished by the selective beta2-adrenergic receptor antagonist, ICI-118551 (0.2 mg/kg). ICI-118551 caused a significant reversal of the plasma K+ decrease but the K+ levels remained higher than control levels. These studies demonstrate that stimulation of beta2-adrenergic receptors causes tremor, most likely from entry of K+ into skeletal muscle and that there is a direct correlation between tremor and hypokalemic response.
 ...
PMID:Quantitation of tremor in response to beta-adrenergic receptor stimulation in primates: relationship with hypokalemia. 1046 54